Equity Research Services-Prepackaged Software

Should You Buy Cellebrite DI Ltd. Stock in 2026?

By CirclFi Research Team · · 13/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Cellebrite DI Ltd. (CLBT) sits in the bottom tier of our quality coverage with a score of 2.8/10. While a weak quality score suggests operational challenges, our valuation models assess if the market has over-discounted the stock at $14.75.

The short answer: 1 of 13 CirclFi valuation models project upside for Cellebrite DI Ltd. (CLBT) at $14.75 — the model consensus leans bearish, with a Quality Score of 2.8/10 and Value-Trap risk of —/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 12 of 13 models suggest overvaluation — majority bearish
  • Quality Score: 2.8/10 — Very Weak — significant concerns
  • Value Trap Risk: —/100 — Not scored
  • Fair Value Range: $1.03 – $15.05 (1360% spread)

Bullish Models

1 / 13

Bearish Models

12 / 13

Quality Score

2.8 /10

Very Weak — significant concerns

Value Trap Risk

— /100
Not scored

Not scored

Model Consensus

13 /13
Active Models

Avg. confidence: 25%

Investment Thesis

The Bull Case

Target: $15.05 (+2.0% upside)

  • Industry tailwind: enterprise adoption could provide meaningful support for Cellebrite DI Ltd.'s revenue and margin trajectory in the Services-Prepackaged Software space.

The Bear Case

Target: $1.03 (-93.0%)

  • According to the CirclFi Quality of Company (QOC) framework, Cellebrite DI Ltd.'s rating of 2.8/10 indicates below-average quality, raising questions about sustainable earnings levels.
  • According to the CirclFi Deep Alpha Valuation Engine, the Dynamic NAV model sees the stock as overvalued with a fair value of $1.03 (-93.0%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +95.0% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.
  • Industry headwind: customer churn acceleration represents a meaningful risk for Cellebrite DI Ltd. and its Services-Prepackaged Software peers.

Peer Benchmarking

CRM Salesforce, Inc.
10.0
CVLT Commvault Systems, I
10.0
EGAN eGain Corporation
10.0
MANH Manhattan Associates
10.0
MSFT Microsoft Corporatio
10.0

See full Services-Prepackaged Software rankings →

Valuation Divergence

Spread

1360%

Fair Value Range

$1.03 – $15.05

A 1360% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

PWERM

$15.05 (+2.0%)

Most Bearish

Dynamic NAV

$1.03 (-93.0%)

Key Risk Factors

Weak Fundamentals

QOC 2.8/10 signals below-average quality.

Model Disagreement

1360% spread signals high variance in projections.

Bearish Consensus

12/13 models suggest overvaluation.

Macro/Sector Risk

Services-Prepackaged Software headwinds could affect earnings trajectory.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View CLBT Data Page →

The Bottom Line

Our valuation engine sends a clear cautionary signal on Cellebrite DI Ltd. at $14.75. 12/13 models flag overvaluation, composite fair value sits at $4.79 (-67.5%), and the risk-reward profile appears unfavorable. Quality at 2.8/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. Cellebrite DI Ltd.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy CLBT stock right now?

Based on CirclFi's multi-model analysis, 1 of 13 models see upside for CLBT at $14.75. The models are divided, which means the investment case depends heavily on your assumptions about Cellebrite DI Ltd.'s future. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Cellebrite DI Ltd.?

Key risks include: a below-average Quality Score of 2.8/10, indicating fundamental weakness; wide model disagreement (1360% spread), signaling high uncertainty; general market and sector-specific risks affecting Services-Prepackaged Software companies. Always diversify and consult a financial advisor.

How does CLBT compare to its competitors?

Among Services-Prepackaged Software peers, CLBT holds a Quality Score of 2.8/10. Comparable companies include CRM (QOC 10.0), CVLT (QOC 10.0), EGAN (QOC 10.0). The relative ranking helps investors identify whether CLBT offers better fundamental quality than alternatives in the same sector.

Is CLBT a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. CLBT's Quality Score of 2.8/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.

What price should I buy CLBT at?

CirclFi does not provide target buy prices or price alerts. However, our 13 active models produce fair value estimates ranging from $1.03 to $15.05. At $14.75, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for CLBT.

View CLBT Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →